NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
Key Details
- 1NIH total investment in the AI4AD project now totals $30.7 million, with a new $12.6 million award supporting the next phase (AI4AD2).
- 2AI4AD2 unites 10 investigators and 23 co-investigators from 10 institutions.
- 3The project integrates whole-genome sequencing, brain imaging, cognitive tests, and biological data from over 58,000 participants across 57 cohorts.
- 4New 'genomic language models' will analyze genomic sequences for disease-associated DNA changes.
- 5AI tools developed previously demonstrated >90% accuracy detecting Alzheimer's markers from over 80,000 brain scans.
- 6The initiative also focuses on inclusive, multi-ancestry research and genome-guided drug discovery.
Why It Matters
This large-scale effort could redefine Alzheimer's diagnosis and treatment by combining AI-powered brain imaging analysis with genomics, enabling precision medicine approaches. It also addresses diversity and reproducibility issues in neuroimaging and biomarker AI research.
Source
EurekAlert
Related News
•EurekAlert
New VIS-Fb Nanobody Probes Transform High-Precision Cellular Imaging
Salk and Einstein researchers have developed visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs) for sharper, multi-color live-cell imaging with minimal background noise.
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.